https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14309 Wed 11 Apr 2018 10:42:10 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41650 Wed 10 Aug 2022 09:04:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34211 Thu 09 Dec 2021 11:02:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24132 24weeks post-treatment). Findings: Among 101 treated, 37% (n=37) had recently injected drugs (past 6months) and 62% (n=63) were receiving OST. Adherence =80% was 86% (n=87). SVR was 74% (75 of 101), with no difference observed by sex (males: 76%, females: 67%, P=0.662). In adjusted analysis, age <35 (versus =45years) [adjusted odds ratio (aOR)=5.06, 95% confidence interval (CI)=1.47, 17.40] and on-treatment adherence =80% independently predicted SVR (aOR=19.41, 95% CI=3.61, 104.26]. Recent injecting drug use at baseline was not associated with SVR. Conclusions: People with a history of injecting drug use and chronic hepatitis C virus attending opioid substitution treatment and community health clinics can achieve adherence and responses to interferon-based therapy similar to other populations, despite injecting drugs at baseline. Younger age and adherence are predictive of improved response to hepatitis C virus therapy.]]> Fri 01 Apr 2022 09:25:51 AEDT ]]>